1 / 20

Olivia Chang, MPH Research and Program Manager Pangaea Global AIDS

Hepatitis C and HIV/HCV Co-infection among Methadone Clients in Dar es Salaam, Tanzania: Prevalence and Predictors. Olivia Chang, MPH Research and Program Manager Pangaea Global AIDS. Presentation Outline. Background Methods Results Conclusions.

vaughan
Download Presentation

Olivia Chang, MPH Research and Program Manager Pangaea Global AIDS

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Hepatitis C and HIV/HCV Co-infection among Methadone Clients in Dar es Salaam, Tanzania: Prevalence and Predictors Olivia Chang, MPH Research and Program Manager Pangaea Global AIDS

  2. Presentation Outline • Background • Methods • Results • Conclusions

  3. Emergence of Injection Drug Use in East Africa UNODC Data

  4. Drivers of the Epidemic in Tanzania • 30,000-50,000 PWID • 15,000-20,000 in Dar es Salaam Prevalence Estimates (Dar) Reported Heroin Use in Tanzania Williams (2009) Nyandindi (2011), Lambdin (2013), Bowring (2013), Matee (2006), TACAIDS (2011), NACP (2014)

  5. Roll-out of Methadone in Dar es Salaam * * Community-based outreach begins (2010) MNH Muhimbili National Hospital MRH Mwananyamala Regional Hospital TRH Temeke Regional Hospital

  6. Methods: Prevalence and Predictors • Study Design: Cross-sectional • Data Sources: Routine programmatic and clinical monitoring data • Study Population: Clients enrolled in methadone between February 2011 to January 2013 at Muhimbili National Hospital • Provider-initiated testing and counseling for HIV and HCV is provided (rapid tests). • Linkage to care and treatment for PLHIV; supportive care for PLHCV

  7. Methods: Prevalence and Predictors • Covariates: demographics, sexual risk factors, injection risk factors, mental health history, legal/criminal history and history of abuse • Outcomes: 1) HCV+ and 2) HIV+/HCV+ • Prevalence Estimates: Percentages with 95% confidence intervals • Statistical Analysis: Binomial regression to estimate adjusted risk ratios with 95% confidence intervals

  8. Results • Methadone clients enrolled: 629 • Clients HCV-screened: 494 (79%)

  9. Results • Sexual Risk Behaviors (last 6 months) • Injection-related Risk Behaviors * Practice of injecting oneself with blood from another person who has recently injected heroin.

  10. Results: Prevalence and Predictors of HCV • HCV+: 57% (95% CI: 53%-61%) Adjusted Risk Ratios for HCV Seropositivity

  11. Results: HIV/HCV Co-infection Overall: 36% (95% CI: 31% – 40%) Total HIV and HCV Screened: 413 (66%)

  12. Results: HIV/HCV Co-infection Overall: 36% (95% CI: 31% – 40%) Among HIV+: 86% (95% CI: 81%-91%) Total HIV and HCV Screened: 413 (66%)

  13. Results: Predictors of HIV/HCV Co-infection Adjusted Risk Ratios for HIV/HCV Co-infection

  14. Results: Predictors of HIV/HCV Co-infection Adjusted Risk Ratios for HIV/HCV Co-infection

  15. Conclusions • Risky injection practices drive transmission. • PWID, particularly women, have a disproportionate burden of disease and are also harder to reach. • Current coverage is inadequate, scale-up of harm reduction is urgently needed.

  16. How do we Respond?

  17. How do we Respond? Care for PWID HCV VL Monitoring Hep A/B immunization Reach female PWID Scale-up NSP and OST Testing and counseling Condom distribution IEC & BCC

  18. How do we Respond? Care for PWID Research/ Policy Affordable and equal access to tx HCV VL Monitoring Hep A/B immunization Simplify/optimize tx regimen Drug interaction studies Reach female PWID Scale-up NSP and OST Testing and counseling Condom distribution IEC & BCC Genotyping Prevalence Estimates

  19. How do we Respond? Care for PWID Research/ Policy Affordable and equal access to tx HCV VL Monitoring Hep A/B immunization Simplify/optimize tx regimen Drug interaction studies Reach female PWID Scale-up NSP and OST Testing and counseling Condom distribution IEC & BCC Genotyping Prevalence Estimates Strengthen M&E systems Train Health Care Workers Decentralize and Integrate Services Advocacy Systems

  20. Acknowledgements

More Related